Amphastar Pharmaceuticals, Inc. (FRA:29A)

Amphastar Pharmaceuticals Statistics

Total Valuation

FRA:29A has a market cap or net worth of EUR 1.09 billion. The enterprise value is 1.41 billion.

Market Cap	1.09B
Enterprise Value	1.41B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	45.95M
Shares Outstanding	n/a
Shares Change (YoY)	-6.16%
Shares Change (QoQ)	-0.94%
Owned by Insiders (%)	9.39%
Owned by Institutions (%)	71.99%
Float	34.80M

Valuation Ratios

The trailing PE ratio is 11.40 and the forward PE ratio is 7.92.

PE Ratio	11.40
Forward PE	7.92
PS Ratio	1.76
PB Ratio	1.64
P/TBV Ratio	6.23
P/FCF Ratio	11.24
P/OCF Ratio	8.36
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.71, with an EV/FCF ratio of 14.63.

EV / Earnings	14.85
EV / Sales	2.27
EV / EBITDA	7.71
EV / EBIT	10.95
EV / FCF	14.63

Financial Position

The company has a current ratio of 3.12, with a Debt / Equity ratio of 0.85.

Current Ratio	3.12
Quick Ratio	2.07
Debt / Equity	0.85
Debt / EBITDA	3.08
Debt / FCF	5.80
Interest Coverage	4.51

Financial Efficiency

Return on equity (ROE) is 14.84% and return on invested capital (ROIC) is 6.72%.

Return on Equity (ROE)	14.84%
Return on Assets (ROA)	5.84%
Return on Invested Capital (ROIC)	6.72%
Return on Capital Employed (ROCE)	10.26%
Revenue Per Employee	303,981
Profits Per Employee	46,914
Employee Count	2,028
Asset Turnover	0.45
Inventory Turnover	2.32

Taxes

In the past 12 months, FRA:29A has paid 20.49 million in taxes.

Income Tax	20.49M
Effective Tax Rate	17.72%

Stock Price Statistics

The stock price has decreased by -45.51% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-45.51%
50-Day Moving Average	21.58
200-Day Moving Average	22.24
Relative Strength Index (RSI)	60.84
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.21

Income Statement

In the last 12 months, FRA:29A had revenue of EUR 616.47 million and earned 95.14 million in profits. Earnings per share was 1.93.

Revenue	616.47M
Gross Profit	304.30M
Operating Income	127.79M
Pretax Income	115.63M
Net Income	95.14M
EBITDA	175.34M
EBIT	127.79M
Earnings Per Share (EPS)	1.93

Balance Sheet

The company has 235.41 million in cash and 559.77 million in debt, giving a net cash position of -324.35 million.

Cash & Cash Equivalents	235.41M
Total Debt	559.77M
Net Cash	-324.35M
Net Cash Per Share	n/a
Equity (Book Value)	662.02M
Book Value Per Share	14.28
Working Capital	370.11M

Cash Flow

In the last 12 months, operating cash flow was 129.78 million and capital expenditures -33.26 million, giving a free cash flow of 96.53 million.

Operating Cash Flow	129.78M
Capital Expenditures	-33.26M
Free Cash Flow	96.53M
FCF Per Share	n/a

Margins

Gross margin is 49.36%, with operating and profit margins of 20.73% and 15.43%.

Gross Margin	49.36%
Operating Margin	20.73%
Pretax Margin	18.76%
Profit Margin	15.43%
EBITDA Margin	28.44%
EBIT Margin	20.73%
FCF Margin	15.66%

Dividends & Yields

FRA:29A does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.16%
Shareholder Yield	6.16%
Earnings Yield	8.77%
FCF Yield	8.90%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:29A has an Altman Z-Score of 2.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.62
Piotroski F-Score	4